Sign in

NCT05593081Recruiting

Multicenter Study of Fulminant Type 1 Diabetes in China

Source: ClinicalTrials.gov · Last updated 25 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study took FT1D(fulminant type 1 diabetes) as the research object, collected the cases of FT1D patients, and described the clinical characteristics of this type of disease. The HLA susceptibility genes of FT1D were identified by PCR and other techniques, taking age-sex-matched healthy subjects as controls and HLA genes as the research entry point.

Status (registry)
Recruiting
Study type
Observational
Enrollment
240 (estimated)
First submitted
18 Oct 2022
Start date
20 May 2022
Primary completion date
31 Dec 2027
Lead sponsor
Second Xiangya Hospital of Central South University
NCT number
NCT05593081

What you commit to

  • Study type: Observational
  • Planned participants: 240
  • From 20 May 2022 to the primary completion date, 31 Dec 2027
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Case reports of previously diagnosed with diabetes were excluded.

Other illness

  • The exclusion criteria were as follows: (1) with heart, brain, liver, kidney or other chronic diseases; (2) with other types of autoimmune diseases; (3) with malignant tumors; (4) with a family history of diabetes.

Other

  • Healthy Volunteers

Who the study is looking for

  • 1\) diabetic ketosis or ketoacidosis occurred soon after the onset of hyperglycemic symptoms; 2) patient presented with plasma glucose ≥16.0 mmol/L and HbA1c \<8.7% at the first visit; and 3) patient had urinary C-peptide excretion \<10 µg/day,fasting serum C-peptide level \<0.10 nmol/L, or postprandial serum C-peptide \<0.17 nmol/L at onset
  • Normal control: The inclusion criteria are as follows: (1) Oral glucose tolerance test (OGTT): fasting blood glucose (FPG) \<5.6 mmol/L and postprandial 2 h blood glucose (PPG) \<7.8 mmol/L. The participants voluntarily signed the informed consent and extracted 3ml of peripheral blood for DNA extraction.

Criteria the registry did not label

  • patients with fulminant 1 diabetes

Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Changsha Central Hospital
Coordinator of this site? Confirm its status
ChangshaChinaRecruiting
The Second Xiangya Hospital of Central South University
Coordinator of this site? Confirm its status
ChangshaChinaRecruiting
The First Affiliated Hospital of Guangzhou Medical University
Coordinator of this site? Confirm its status
GuangzhouChinaRecruiting
Hainan Provincial People's Hospital
Coordinator of this site? Confirm its status
HaikouChinaRecruiting
Yunnan Provincial People's Hospital
Coordinator of this site? Confirm its status
KunmingChinaRecruiting
The First Affiliated Hospital of NanChang University
Coordinator of this site? Confirm its status
NanchangChinaRecruiting
The First Affiliated Hospital of Guangxi Medical University
Coordinator of this site? Confirm its status
NanningChinaRecruiting
Quanzhou First People's Hospital
Coordinator of this site? Confirm its status
QuanzhouChinaRecruiting
Yancheng Third People's Hospital
Coordinator of this site? Confirm its status
YanchengChinaRecruiting
Guizhou Provincial People's Hospital
Coordinator of this site? Confirm its status
ZunyiChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.